A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease  by Hovingh, G. Kees et al.
A
E
T
G
J
E
M
A
P
d
v
a
c
s
o
3
1
A
C
N
M
T
V
o
K
1
G
R
a
Journal of the American College of Cardiology Vol. 44, No. 7, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.070HDL and Coronary Artery Disease
Novel ApoA-I Mutation (L178P) Leads to
ndothelial Dysfunction, Increased Arterial Wall
hickness, and Premature Coronary Artery Disease
. Kees Hovingh, MD,* Alison Brownlie, PHD,† Radjesh J. Bisoendial, MD,* Marie Pierre Dube, PHD,†
ohannes H. M. Levels, PHD,* Wilma Petersen, BSC,* Robin P. F. Dullaart, MD, PHD,‡
rik S. G. Stroes, MD, PHD,* Aeilko H. Zwinderman, PHD,§ Eric de Groot, MD, PHD,*
ichael R. Hayden, MD, PHD, CHB,† Jan Albert Kuivenhoven, PHD,* John J. P. Kastelein, MD, PHD*
msterdam and Groningen, The Netherlands; and Vancouver, British Columbia, Canada
OBJECTIVES We investigated the consequences of an apolipoprotein A-I (apoA-I) gene defect with regard
to lipid metabolism, endothelial function, arterial wall thickness, and coronary artery disease
(CAD) risk.
BACKGROUND Due to limited numbers of carriers of the apoA-I defects, data on the consequences of such
defects have remained inconclusive.
METHODS Lipids and lipoproteins were measured in 54 apoA-I (L178P) carriers and 147 nonaffected
siblings. Flow-mediated dilation (FMD) was assessed in 29 carriers and 45 noncarriers, and
carotid intima-media thickness (IMT) could be determined in 33 heterozygotes and 40
controls. Moreover, CAD risk was evaluated for all apoA-I mutation carriers.
RESULTS Heterozygotes exhibited lower plasma levels of apoA-I (50%; p 0.0001) and high-density
lipoprotein cholesterol (63%; p  0.0001). In addition, carriers had impaired FMD (p 
0.012) and increased carotid IMT (p  0.001), whereas multivariate analysis revealed that
heterozygotes had a striking 24-fold increase in CAD risk (p  0.003).
CONCLUSIONS Heterozygosity for a novel apoA-I mutation underlies a detrimental lipoprotein profile that
is associated with endothelial dysfunction, accelerated carotid arterial wall thickening, and
severely enhanced CAD risk. Importantly, the extent of atherosclerosis in these subjects was
similar to the burden of premature arterial wall abnormalities seen in patients with familial
hypercholesterolemia. These data illustrate the pivotal role in humans of apoA-I in the
protection against CAD. (J Am Coll Cardiol 2004;44:1429–35) © 2004 by the American
College of Cardiology Foundationy
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frospective epidemiologic studies have shown that high-
ensity lipoprotein (HDL) cholesterol plasma levels are in-
ersely related to coronary artery disease (CAD) risk (1). This
See page 1436
grees with the finding that low plasma levels of HDL
holesterol are a common form of dyslipidemia in patients
uffering from premature CAD (2). Moreover, the importance
f increasing HDL cholesterol levels is illustrated by a 2% to
% reduction of major cardiovascular events associated with a
mg/dl (0.026 mmol/l) increase of HDL cholesterol on five
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f the Netherlands Heart Foundation (2000D039). Drs. Hovingh and Albert
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Manuscript received January 20, 2004; revised manuscript received June 2, 2004,bccepted June 22, 2004.ears of fenofibrate treatment (3). The atheroprotective role of
DL is partly ascribed to its role in reverse cholesterol
ransport, by which HDL transports cholesterol from periph-
ral cells to the liver and steroidogenic organs (4). In addition,
DL displays significant anti-oxidant and anti-inflammatory
roperties (5).
Apolipoprotein A-I (apoA-I), the major protein constituent
f the HDL particle, is critical to HDL metabolism. It
rovides HDL with structural integrity and is required for
ormal HDL function. Human apoA-I is expressed in the
iver and small intestine, and secretion into plasma results in de
ovo HDL production. In this process, apoA-I is lipidated
hrough adenosine triphosphate (ATP)-binding cassette AI
ransporter-mediated cholesterol efflux, which results in the
ormation of disc-shaped pre-beta1 HDL particles (6). Leci-
hin/cholesterol acyltransferase, an enzyme that uses apoA-I as
cofactor, subsequently esterifies free cholesterol on the nas-
ent HDL particle, which leads to the formation of larger and
pherical HDL. Finally, apoA-I has been shown to play an
mportant role in one of the last steps of the reverse cholesterol
ransport process. As a ligand of the scavenger receptor B-I, it
acilitates the specific uptake of cholesteryl esters from HDL
y the liver, albeit in mice (7). It is not known whether, in
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Atherosclerosis in ApoA-I (L178P) Carriers October 6, 2004:1429–35umans, apoA-I also binds to the recently described novel
epatic receptor (ectopic beta chain of ATP synthase) to enable
olo-HDL particle uptake (8).
To date, over 40 apoA-I gene defects have been de-
cribed, which may have severe consequences for HDL
etabolism (9). The risk of CAD associated with these
poA-I gene defects, however, has not been elucidated. This
s primarily due to limited numbers of carriers of apoA-I
efects, and, as a consequence, inconclusive data are pro-
ided by the literature. Some apoA-I mutations supposedly
nderlie CAD (L159P) (10), whereas others show no effect
L144R) (11) or even protection against CAD (R173C)
12).
We identified a novel apoA-I mutation (L178P) in
utch families suffering from familial hypo-alpha-
ipoproteinemia. We report on the consequences of this
poA-I mutation for lipid metabolism in a large group of
eterozygotes compared with family controls. As surrogate
nd points for CAD, we subsequently measured endothelial
unction by flow-mediated dilation (FMD) and carotid
ntima-media thickness (IMT). Finally, cardiovascular end
oints in the affected and control individuals were scored
nd assessed by multivariate analyses.
ETHODS
tudy population. The subjects were recruited from a
utch population-based study to identify genes that control
DL cholesterol levels (performed in collaboration with the
enter for Molecular Medicine and Therapeutics at the
niversity of British Columbia, Canada; and Xenon Ge-
etics Inc., British Columbia, Canada). The population
omprised 94 probands who met the following inclusion
riteria: 1) HDL cholesterol plasma level below the fifth
ercentile for age and gender; 2) absence of other primary or
econdary lipid disorders (i.e., diabetes, alcohol abuse); and
) high likelihood of inherited low HDL cholesterol (de-
ned as an HDL cholesterol below the fifth percentile for
ge and gender and absence of other primary or secondary
ipid disorders in at least one first-degree family member).
nformed consent was obtained from all subjects for plasma
ampling, storage, genetic analysis, and vascular tests, under
protocol approved by the ethics committee of the Aca-
emic Medical Center in Amsterdam. Past medical history,
resence of cardiovascular risk factors, use of medication,
nd information on geographic origin of the probands were
Abbreviations and Acronyms
apoA-I  apolipoprotein A-I
CAD  coronary artery disease
FMD  flow-mediated dilation
HDL  high-density lipoprotein
IMT  intima-media thickness
LDL  low-density lipoproteinssessed by a questionnaire. mNA analysis and mutation detection. DNA was ex-
racted from peripheral blood leukocytes, as described pre-
iously (13). Genotyping, linkage analysis, haplotyping, and
equencing were used in an attempt to localize the molecular
efects in families segregating low HDL. In one of the
amilies (Family #11), this exercise resulted in the identifi-
ation of a novel C/T point mutation at nucleotide 643 in
xon 4 of the ApoA-I gene (using Genbank entry
I4557320 as reference sequence), predicting the exchange
f a leucine for a proline residue at position 178 (L178P) in
he mature ApoA-I protein. The leucine residue at position
78 is highly conserved with the exception of the pig, where
his residue is instead a phenylalanine (14). The variant was
ound on the affected haplotype and fully co-segregated
ith hypo-alpha-lipoproteinemia in this family. In support
f the causal nature of this mutation, the sequence variant
as not detected in 374 control chromosomes (data not
hown).
Using polymerase chain reaction-restriction fragment
ength polymorphism analysis, we identified five additional
eterozygous carriers in the remaining 93 low HDL pro-
ands (Family #8, #12, #28, #61, and #94). It is of note that
ll six probands originate from the same geographic region
n the Netherlands, suggesting common ancestry. A Markov
hain Monte Carlo with a bayesian integration approach
15) (described under Statistical Analysis) was used for the
stimation of age of the mutation.
aboratory analysis. Blood samples were drawn after an
vernight fast. Total plasma cholesterol and triglycerides
ere determined by an enzymatic colorimetric procedure
CHOD-PAP, Boehringer, Mannheim, Germany); HDL
holesterol was measured as cholesterol remaining after
recipitation of apoB-containing lipoproteins by MnCl2.
ow-density lipoprotein (LDL) cholesterol was calculated
sing the Friedewald formula. Plasma apoA-I and apoB
oncentrations were determined by immunonephelometry.
mmunoelectrophoresis was used to quantify LpAI (Sebia,
sy-les Moulineaux, France), and LpAI:AII was calculated
s the difference between total apoA-I and LpAI concen-
rations (16).
low-mediated dilation. Flow-mediated vasodilation was
easured as previously described (17). In short, FMD was
ssessed after 10 h of fasting. A blood pressure cuff was
laced below the elbow of the right arm. After a 10-min
est, the diameter of the brachial artery was visualized in the
ntecubital fossa using a 7.5-Mhz transducer. Reactive
yperemia was induced by inflating the blood pressure cuff
o 220 mm Hg for 4 min. After release of the cuff, reactive
asodilation was monitored at 30-s intervals during 5 min.
all track measurements were performed and digitally
tored by the same sonographer, who was blinded as to the
enetic status of the participants. Baseline vessel luminal
iameter was calculated as the average of three baseline
easurements. The FMD results were calculated using the
ollowing equation: (maximal lumen after hyperemia 
ean diameter at baseline)/diameter at baseline  100%.
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October 6, 2004:1429–35 Atherosclerosis in ApoA-I (L178P) Carriersntima-media thickness. The IMT measurements were
erformed as earlier described (18). In short, high-
esolution B-mode ultrasound images were acquired us-
ng an Acuson 128XP/10v (Acuson Corp., Mountain-
iew, California), with a 7.0-MHz linear array trans-
ucer. Segments of 10 mm of the following predefined
all segments were scanned: the common carotid artery,
he carotid bulb, and the internal carotid artery. The
cquired images were saved as JPEG image files. One
mage reader, blinded as to the genetic status of the
atient, measured the IMT of the far wall of those
egments. The mean combined IMT of these three
egments was used to compare carriers and noncarriers.
tatistical analysis. A Markov Chain Monte Carlo with
bayesian integration approach was applied using
MLE2.14 (15) to estimate the age of the ApoA-I
L178P) mutation. The six pedigree disease haplotypes and
6 independent control haplotypes taken from the pedi-
rees, genotyped at 10 microsatellite markers spanning 12
M, were used for the estimation. Program parameters were
et to 1,000,000 replications; average population growth was
alculated to 0.18 per generation for the last 300 years; and
he haplotype fraction sampled in the Northern region of
he Netherlands (Friesland) was set to 0.012.
Continuous outcomes were compared between affected
nd unaffected subjects using the general linear mixed model
ith pedigree number as a random factor to account for the
ssociation between subjects from the same pedigree. For
ichotomous outcomes, a similar generalized linear mixed
odel was applied with pedigree as random factor. The Cox
roportional hazard model extended with a frailty-
arameter per pedigree was used to determine event-free
urvival rates for affected and unaffected subjects. The
roportional hazard conditions were met. Analyses were
erformed using the Statistical Program for the Social
ciences (Version 10.0, SPSS Inc., Chicago, Illinois) and
-plus for the Cox regression with frailty parameter. The
ignificance level was set at p 0.05 (two-tailed).
ESULTS
emographic and genetic characteristics of study co-
ort. Active recruitment in six kindreds yielded 54 het-
rozygotes for the apoA-I defect and 147 family controls.
he number of cases and controls in the different pedigrees
ere distributed as follows—Family #11: 12 carriers and 28
ontrols; Family #8: 7 carriers and 4 controls; Family #12:
3 carriers and 49 controls; Family #28: 3 carriers and 11
ontrols; Family #61: 6 carriers and 5 controls; and Family
94: 13 carriers and 50 controls.
All individuals were Caucasian of Dutch descent and
ived in an isolated part in the Northern region of the
etherlands. The demographic data of carriers and noncar-iers are given in Table 1. Mean age, age range, male/female tatios, and the prevalence of hypertension (defined by the
se of antihypertensive medication) and smoking were
imilar in both groups.
Univariate linear regression revealed that the effects of the
poA-I mutation described in subsequent sections were not
ifferent among the six families, suggesting homogeneity of
he total population. Genotyping and haplotyping of these
amilies with genetic markers in close proximity to the
poA-I gene demonstrated that they shared a 2.67-cM
aplotype segment, suggestive of common ancestry. Two
indreds even shared a 7.62-cM haplotype. The age of the
poAI L178P mutation was estimated at 20 generations,
ith the 95% confidence interval (CI) ranging from 12 to 35
enerations.
ipids, lipoproteins, and apolipoproteins. Compared
ith control subjects, heterozygotes for the apoA-I defect
resented with a 52% mean decrease of apoA-I levels (0.70
s. 1.47 g/l, p  0.0001) (Table 2) and a 62% decrease of
DL cholesterol levels (0.44 vs. 1.22 mmol/l, p  0.0001).
hese reductions of HDL cholesterol were reflected by a
ignificant decrease of HDL containing only apoA-I
LpA-I: 0.31 vs. 0.60 g/l, p 0.0001) and HDL containing
oth apoA-I and apoA-II (LpA-I:A-II: 0.39 vs. 0.87 g/l, p
0.0004). In the absence of effects on triglycerides and
DL cholesterol, the reduction of HDL cholesterol was
able 1. Demographic Characteristics of Heterozygotes for the
poA-I (L178P) Defect and Unaffected Family Controls
ApoAI (L178P)
Heterozygotes
(n  54)
Noncarriers
(n  147)
ean age (yrs) 37.6  19.2 37.9  16.8
ge range 3–81 0.8–90
ales/females 32/22 68/79
moker (%) 9 (17.6) 48 (30.6)
ypertension (%) 4 (7.4) 9 (6.1)
MI (kg/m2) 24.9  5.0 25.0  5.3
ll data are expressed as the mean value  SD or number (%) of subjects. Differences
etween carriers and noncarriers were not significant.
BMI  body mass index.
able 2. Lipids, Lipoproteins, and Apolipoproteins of Carriers
nd Noncarriers of ApoA-I Mutation (L178P)
ApoAI (L178P)
Carriers
(n  54)
Noncarriers
(n  147) p Value
poA-I (g/l) 0.70 0.31 1.47 0.33 0.0001
DL cholesterol (mmol/l) 0.44 0.22 1.22 0.36 0.0001
LpA-I (g/l) 0.31 0.10 0.60 0.13 0.0001
LpA-I:A-II (g/l) 0.39 0.87 0.0004
C (mmol/l) 4.20 1.06 4.72 0.99 0.001
G (mmol/l) 1.31 0.88 1.19 1.28 0.09
DL cholesterol (mmol/l) 3.16 0.92 2.98 0.91 0.23
ipoprotein(a) (mg/l) 182.78 209.0 213 165.9 0.45
poB (g/l) 0.99  0.26 0.89 0.20 0.21
ll data are given as the mean value  SD.
ApoA-I  apolipoprotein A-I; apoB  apolipoprotein B; HDL  high-density
ipoprotein; LpA-I  HDL containing apoA-I; LpA-I:A-II  HDL containing
poA-I and apoA-II; LDL low-density lipoprotein; TC total cholesterol; TG
riglycerides.
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Atherosclerosis in ApoA-I (L178P) Carriers October 6, 2004:1429–35irrored by a decrease of total cholesterol levels (4.20 vs.
.72 mmol/l, p  0.001) in apoA-I (L178P) heterozygotes.
ipoprotein(a) levels were not different in affected and
naffected subjects.
low-mediated vasodilation. Flow-mediated dilation
ould be assessed in 29 carriers (18 men and 11 women) and
igure 1. Log-transformed (logFMD) results are significantly lower in
arriers of the apoA-I (L178P) mutation compared with family controls.
nverted triangles  apoA-I (L178P) carriers; circles  family controls.
igure 2. Mean combined carotid intima media thickness (IMT) increase
he rate of progression of carotid wall thickening over time is similar in L17
ApoA-I (L178P) carriers; open diamonds  patients with FH;   family5 family controls (24 men and 21 women). Controls were
ignificantly younger than carriers (29.2 vs. 40.7 years, p 
.01). We found no association between age and FMD in
his cohort (p  0.18). In addition, smoking habits and the
revalence of medically treated hypertension did not differ
mong both groups. The median FMD was significantly
educed in apoA-I (L178P) carriers compared with family
ontrols (3.5% vs. 5.5%, p 0.012) (Fig. 1). This difference
emained significant after exclusion of heterozygotes (n 5)
ith from CAD.
MT. The IMT measurements were performed in 33
eterozygotes (12 women and 21 men) and 40 family
ontrols (18 women and 22 men). The mean carotid IMT
f mutation carriers was significantly increased compared
ith that of family controls (0.79 vs. 0.56 mm, p 0.0001).
he cross-sectional data were subsequently plotted against
ge, which suggested that the progression of carotid wall
hickening over time differed significantly between carriers
nd controls. Our data show a 0.0047- or 0.0082-mm
combined) carotid IMT increase per year of age in controls
nd heterozygotes, respectively (p  0.001) (Fig. 2). The
mpact of the apoA-I (L178P) mutation is clear when
onsidering similar rates of carotid wall thickening in a
ohort of 215 patients with familial hypercholesterolemia
Fig. 2) (19).
ear of age is significantly higher in heterozygotes compared with controls.
terozygotes and familial hypercholesterolemia (FH) patients. Solid circlesper y
8P hecontrols.
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October 6, 2004:1429–35 Atherosclerosis in ApoA-I (L178P) Carriersardiovascular events. Among the 54 L178P heterozy-
otes, eight subjects (15%) had CAD (i.e., acute myocardial
nfarction, coronary artery bypass graft operation, or coro-
ary angioplasty), of which six occurred at a premature age
before the age of 55 and 60 years in men and women,
espectively). In contrast, only two of 147 control subjects
1.4%) suffered from an event, of which none occurred
rematurely. Using univariate analysis, this difference was
ighly statistically significant (p 0.0001; data not shown).
n multivariate analysis, controlling for age, gender, and
edigree, the apoA-I (L178P) carrier status was found to
onvey a 24-fold increase in the risk of developing CAD
Table 3). The odds ratio to develop CAD when carrying
he apoA-I gene mutation was 18.9 (CI 2.3 to 153.8, p 
.003) after excluding the six probands. The difference in
vent-free survival between carriers and controls, as shown
n Figure 3, further illustrates the severe consequences of
his mutation (p  0.008).
ISCUSSION
his report shows the detrimental consequences of a novel
poA-I (L178P) mutation on HDL metabolism, endothe-
ial function, carotid arterial wall IMT and CAD risk in a
opulation comprising 54 heterozygous carriers. The novel
efect was identified in six families, all originating from the
ortheastern part of the Netherlands. Evidence of a
ounder effect for L178P was obtained from haplotype
able 3. Multivariate Analysis of Risk of Coronary Artery
isease Attributable to the L178P Mutation Carrier Status
Controlled for Age, Gender,
and Pedigree n OR (95% CI)
p
Value
ncluding pedigree probands
CAD risk (all ages) 201 24.1 (3.2–179.1) 0.0009
CAD risk (age 20 yrs and over) 167 23.7 (3.2–174.6) 0.0009
xcluding pedigree probands
CAD risk (all ages) 195 18.9 (2.3–153.8) 0.0030
CAD risk (age 20 yrs and over) 161 18.5 (2.3–148.0) 0.0030
AD  coronary artery disease; CI  confidence interval; OR  odds ratio.
igure 3. Event-free survival is significantly lower in apoA-I (L178P)
arriers than in controls. Bottom broken line  apoA-I (L178P) carriers;pop line  family controls. p  0.008.nalysis, which demonstrated that all carriers share a
.67-cM haplotype surrounding the gene.
poA-I (L178P): effects on apoA-I levels, HDL choles-
erol, and triglycerides. Although we observed a 50%
ecrease of apoA-I levels in apoA-I (L178P) carriers,
eterozygotes for other apoA-I defects have been associated
ith even greater apoA-I reductions (up to 80%) (10,20).
his has been attributed to dominant negative effects of
ome mutations, and, possibly, L178P does not exhibit such
roperties. In this respect, it is of interest to note that we
ere not able to detect apoA-I (L178P) in plasma by means
f mass spectrometry of the apoA-I protein moiety of
solated HDL (data not shown). This suggests that the
178P variant is not properly processed in the cell, resulting
n absent or greatly diminished secretion into the circula-
ion. Alternatively, the mutant protein may be hypercatabo-
ized on secretion (thereby rendering plasma levels too low
or detection), an effect that has been described for other
poA-I variants (21,22). These data imply that the effects
bserved can be solely attributed to half normal levels of
ild-type apoA-I.
Heterozygous carriers of the apoA-I (L178P) defect
resented with 62% reductions in HDL-C. Similar reduc-
ions have been described for other apoA-I mutations
23,24) although some reports describe HDL-C reductions
p to 80% of normal (24). Finally, we noted no effects on
G levels, which is in contrast with a study that revealed
igher TG levels in men suffering from an other apoA-I
delta K107) defect (25).
poA-I (L178P): cardiovascular disease. Although mu-
ine studies have unequivocally shown that apoA-I protects
gainst atherosclerosis (26,27), and epidemiologic data in
umans clearly indicate that apoA-I levels are a strong
redictor of CAD (28), susceptibility for CAD has been
hown to vary significantly between carriers of apoA-I
efects. Ten of 22 apoA-I–deficient subjects (13 different
amilies) have been described to suffer from CAD to various
egrees (29–33).
It is of interest to note that two publications described
utations at the same amino acid position. Two heterozy-
ous carriers for the Leu178His defect were shown to suffer
rom low HDL cholesterol and amyloidosis, but no signs of
AD were reported (34). Interestingly, no amyloidosis was
bserved in our L178P mutation carriers. The majority of
poA-I mutations associated with amyloidosis change the
soelectric point of the protein (14). This might underlie the
ifference in clinical phenotype between L178H and
178P. The L178H introduces a positively charged residue,
hereas L178P does not. Also, it should be noted that the
178H protein was identified in the plasma of its carriers,
hile this was not the case in heterozygous carriers of the
178P defect. During the preparation of this manuscript,
kewaki et al. (35) reported on a 51-year-old female ho-
ozygote for a premature stop codon at residue 178
nderlying HDL cholesterol deficiency (0.08 mmol/l) and
remature heart failure. In this case, the number of carriers
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Atherosclerosis in ApoA-I (L178P) Carriers October 6, 2004:1429–35n  3) left no opportunity to investigate the direct
orrelation between the mutation and the risk for CAD.
aken together, the relatively small number and young age
f individuals with apoA-I gene defects have until now
ompromised detailed studies into CAD risk.
Some of these difficulties can be overcome by using
urrogate markers to assess atherosclerotic burden, such as
MD and carotid artery IMT (17,36,37). Both FMD and
MT correlate with established risk factors and have been
hown to have predictive value for future vascular events
17). It is clear from our data that heterozygotes for apoA-I
L178P) suffer from endothelial dysfunction as compared
ith family controls, which is likely related to the low levels
f HDL cholesterol in these patients. This hypothesis is
upported by experiments in which infusion of reconstituted
DL acutely improved endothelial function in patients
ith isolated low HDL cholesterol levels, due to ABCA1
efects (38). It is well recognized that impaired endothelium-
ependent vasomotor response, caused by diminished nitric
xide bioavailability, precedes structural arterial wall alter-
tions. This, in turn agrees with our finding of an increased
arotid IMT in affected subjects compared with family
ontrols. However, we needed to account for the difference
n age between the two groups. We therefore calculated the
ate of progression of arterial wall thickening by plotting the
ean carotid artery wall thickness against age. The rate of
rogression in affected subjects was found to be significantly
ncreased.
Finally, the size of our cohort allowed us to not only
orrelate apoA-I (L178P) with low HDL cholesterol, re-
uced FMD, and increased IMT progression, but also with
definite increased risk for cardiovascular complications.
ultivariate analysis revealed a dramatic 24-fold increase in
AD, as defined by myocardial infarction, coronary artery
ypass graft surgery, and percutaneous transluminal coro-
ary angioplasty.
Together, our data illustrate that the L178P defect is
eleterious. This brings us to address IMT measurements in
arriers of another interesting mutation in apoA-I denoted
s apoA-I-Milano (R173C). In contrast to all other apoA-I
efects, apoA-I-Milano has been described to be beneficial
espite the fact that carriers present with a 60% reduction in
DL cholesterol (39). It has been described that this
ariant has increased potential to promote cellular choles-
erol efflux (40). Others have recently shown that infusions
f ApoA-I-Milano/phospholipid complexes in CAD pa-
ients result in a significant regression of coronary plaque
41). Regarding IMT, 21 heterozygous carriers of the
poA-I-Milano (R173C) mutation were found to have
imilar average thicknesses of carotid segments compared
ith control subjects (n  42), further underlining the
istinct properties of this peculiar Milano variant (39).
onclusions. We unambiguously show that isolated low
DL cholesterol due to heterozygosity for apoA-I (L178P)
s marked by endothelial dysfunction, accelerated carotid
rterial wall thickening, and an increased incidence ofremature vascular events compared with their family con-
rols. In this cohort, genetically defined low HDL choles-
erol appears equally detrimental as hereditary high LDL
holesterol with respect to IMT progression. The data
nderscore the pivotal importance of normal apoA-I and
DL cholesterol levels as a defense against all stages of
ardiovascular disease and furthermore indicate that thera-
eutic intervention to raise HDL cholesterol may be equally
ffective to reduce CAD risk as drugs that lower LDL
holesterol.
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